GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-4.37%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$522M
AUM Growth
+$522M
(-19%)
Cap. Flow
-$79.9M
Cap. Flow
% of AUM
-15.31%
Top 10 Holdings %
Top 10 Hldgs %
58.05%
Holding
42
New
7
Increased
15
Reduced
8
Closed
9
Top Buys
| 1 |
Merus
MRUS
|
$17.8M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$15.8M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$15.7M |
| 4 |
Context Therapeutics
CNTX
|
$14.9M |
| 5 |
Cytokinetics
CYTK
|
$14.7M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$44.7M |
| 2 |
Insmed
INSM
|
$35.2M |
| 3 |
Apogee Therapeutics
APGE
|
$26.6M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$26.2M |
| 5 |
AnaptysBio
ANAB
|
$23.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UroGen Pharma
URGN
$900M
| $48.8M | 9.34% | 2,906,259 +285,714 | +11% | +$4.79M |
|
2
Neurogene
NGNE
$264M
| $36.5M | 7% | 1,004,291 | – | – |
|
|
ABVX
3
Abivax
ABVX
$6.12B
| $32.7M | 6.26% | 2,472,188 -16,295 | -0.7% | -$215K |
|
|
4
Merus
MRUS
$4.98B
| $31M | 5.93% | 523,288 +300,000 | +134% | +$17.8M |
|
5
Pliant Therapeutics
PLRX
$101M
| $28.3M | 5.43% | 2,636,864 +785,000 | +42% | +$8.44M |
|
6
Arcellx
ACLX
$3.85B
| $27.2M | 5.2% | 492,000 +192,000 | +64% | +$10.6M |
|
7
Dynavax Technologies
DVAX
$1.19B
| $26.7M | 5.11% | 2,374,000 +1,109,080 | +88% | +$12.5M |
|
8
Evolus
EOLS
$494M
| $26.6M | 5.1% | 2,451,772 +1,772 | +0.1% | +$19.2K |
|
|
9
Cytokinetics
CYTK
$4.23B
| $25.7M | 4.92% | 474,202 +272,000 | +135% | +$14.7M |
|
10
Dianthus Therapeutics
DNTH
$759M
| $19.6M | 3.76% | 757,929 +132,929 | +21% | +$3.44M |
|
|
11
Insmed
INSM
$28.8B
| $16.8M | 3.21% | 250,000 -525,585 | -68% | -$35.2M |
|
12
Zura Bio
ZURA
$133M
| $16.2M | 3.11% | 4,642,241 +1,884,501 | +68% | +$6.6M |
|
|
13
KalVista Pharmaceuticals
KALV
$678M
| $15.8M | 3.02% | +1,338,568 | New | +$15.8M |
|
|
14
Ionis Pharmaceuticals
IONS
$6.79B
| $15.7M | 3.01% | +330,000 | New | +$15.7M |
|
|
15
Context Therapeutics
CNTX
$75.4M
| $14.9M | 2.85% | +7,419,355 | New | +$14.9M |
|
16
Amicus Therapeutics
FOLD
$2.34B
| $14.8M | 2.84% | 1,495,500 | – | – |
|
|
OPTN
17
DELISTED
OptiNose
OPTN
| $14.3M | 2.73% | 13,727,097 +4,940,779 | +56% | +$5.14M |
|
18
Esperion Therapeutics
ESPR
$448M
| $12.9M | 2.46% | 5,791,594 -2,208,406 | -28% | -$4.9M |
|
19
Voyager Therapeutics
VYGR
$186M
| $12.7M | 2.43% | +1,601,527 | New | +$12.7M |
|
20
Outlook Therapeutics
OTLK
$37.8M
| $12.6M | 2.41% | 1,701,510 +221,510 | +15% | +$1.63M |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$399M
| $12M | 2.29% | 3,441,667 +2,275,000 | +195% | +$7.92M |
|
22
Jasper Therapeutics
JSPR
$45.5M
| $9.13M | 1.75% | 402,015 -5,535 | -1% | -$126K |
|
23
Olema Pharmaceuticals
OLMA
$375M
| $8.62M | 1.65% | +796,880 | New | +$8.62M |
|
24
Terns Pharmaceuticals
TERN
$609M
| $7.83M | 1.5% | 1,149,406 -160,569 | -12% | -$1.09M |
|
25
Viridian Therapeutics
VRDN
$1.5B
| $6.51M | 1.25% | 500,000 -835,000 | -63% | -$10.9M |
|